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Abstract 
The prevalence of long term survivors after cancer treatment is increasing and a large 
number of patients are at risk for development of treatment-related sequelae. With 
limitation of health care resources, low cost methods are needed to screen this population 
for sequelae. 
A total of 255 prostate cancer patients treated with curative radiotherapy at one institution 
was identified and responses to self-reported questionnaires based on Soma score for 
rectal and urinary symptoms were analyzed and compared with a similar questionnaires 
filled in by an experienced study nurse during patient interview. 
Results: 65% of living patients returned the questionnaires and 51% showed up for the 
interview. The median follow up time after irradiation was 6,9 years. 57% of the patients 
scored the same as the nurse in an interview setting, while 35% scored higher in the self 
reported forms than in the interview scores. Overall, the self-reported questionnaire 
identified 97% of patients with scores >2 at interview. 
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Conclusion: Self reported questionnaires may be a low cost method to help screen 
populations at risk for treatment related sequelae after prostate irradiation.  
 
Introduction 
Fortunately, there are an increasing number of patients that are long term survivors after 
cancer therapy [1]. A prevalence of 3,9% of the total population in Norway has been 
reported in 2008 and similar figures have been reported from other countries in the 
western world including USA. Radiotherapy is a major cancer treatment modality. 
However, curative radiotherapy is often given with dose-fractionation schedules that may 
result in normal tissue damage. Normal tissue injury may thus be the main limiting factor 
for the curative potential of radiotherapy in local or locally advanced neoplasms and 
these patients are at risk for development of radiation sequelae. 
In times with limitation of resources, follow up by specialists may be of short duration 
and treatment related sequelae may remain partly undetected as late normal tissue 
reactions may take a long time to develop. There is thus a need for low cost methods that 
can detect these sequelae and thus ensure that the patients can get the help needed as well 
as ensure optimal quality of the cancer care provided. Completion of questionnaires 
assessing long-term effects may provide a cost-effective method to identify patients with 
adverse reactions in need of medical help. We tested this hypothesis in a sample of long 
term survivors after prostate radiotherapy. 
 
Patients and Methods 
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During the 14 year period from 1984 to 1998 a total of 314 prostate cancer patients were 
irradiated with curative intent at Ullevaal University Hospital in Norway and 255 patients 
were alive at time for follow up and included in the present study. The majority of the 
patients were treated after 1991. This was generally at a time before neoadjuvant and 
adjuvant hormonal treatment had been implemented and all these patients were treated 
with 70,00 Gy given with 2,00 Gy daily fractions. Generally, a three-dimensional 
conformal CT plan was used and the irradiation technique involving three fields where 
one field was administered from the front and two oblique fields from posterior with the 
patients in prone position. Only a few patients (39) underwent lymph node staging before 
irradiation. For planning, the internal margin and set up margin was set to 1,5 cm in 
accordance with treatment protocol SPCG VII developed by SPCG (Scandinavian 
Prostate Cancer Group).  
According to a modified D’ Amico risk group classification, 83% of the patients could be 
classified as high risk (T3 or PSA> 20 or WHO grade 3), 16% were at intermediate risk 
(T2 or PSA 10-20 or WHO grade 2): and only 1% were categorized as low risk (T1, PSA 
<10 and WHO grade 1) [2]. The median age at radiotherapy was 67 years (64-70 as 25th 
and 75th percentiles) and the median PSA was 22,5 µg/L (11,5-41,6 µg/L). 
The median follow up time from radiotherapy was 6,9 years and the cumulative follow-
up time was 2084 patient-years. Urinary and rectal normal tissue reactions were assessed 
by SOMA scores [3-4,], appendix 1 and 2. The patients were first contacted by mail and 
invited to fill in a questionnaire with the symptomatic scores for urinary and rectal 
complications based on the SOMA scale, translated to Norwegian [5], appendix 3. Pre-
stamped envelopes for return mail were supplied The answers were optically read and 
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computed into a Microsoft Access database. Along with the questionnaire the patients 
were asked if they would like to come for a consultation, which took place approx 4 
months later. At consultation, the patients were assessed by the same experienced 
research nurse and rectal and urinary symptomatic scores were again recorded.  
 
 
Statistical methods 
Descriptive data are presented as median values with 25th and 75th percentiles (25p, 75p) 
or proportions. To compare self-reported scores and interview scores we computed 
proportions of pairs for which clinicians and patients gave an identical score or diverged. 
Spearmann rank correlation coefficient was used to detect concordance between self-
reported scores and interview scores. We also dichotomised symptom scores into ≥2 and 
≥3 categories. Sensitivity and specificity were computed for symptom scores ≥2 using 
interview scores as a gold standard. Further, the Chi-square test detected associations 
between categorical independent variables. All p-values are two-sided, and a 5% 
significance level was used. Statistical analysis was performed using SPSS for Windows, 
version 15 (SPSS Inc., Chicago, IL, USA). 
 
Results 
A total of 165 patients i.e. 65% returned a completed questionnaire by mail and 151 
patients replied that they wanted to come for a consultation but only a total of 130 
patients i.e. 51% of patients alive showed up for consultation. 
In the self-reported questionnaires a total of 61% reported toxicity with grade > 2 from 
the bladder/urethra and 66% from the rectum. Grade > 3 bladder/urethra and rectum 
toxicity was reported as 25% and 12,5% respectively. In the interview setting comparable 
figures were lower with only 48% graded as toxicity grade > 2 from the bladder/urethra 
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and 32,8% from rectum. Only 16% toxicity grade > 3 were detected for both 
bladder/urethra and rectum. 
The frequencies of toxicity scores detected are shown in Table 1 where the self-reported 
scores are shown in black and the scores at interview are shown in red. 
 
To illustrate the agreement or disagreement between patients and clinician, Figure 1 
depicts columns of different scores of each side effects where patients or clinicians 
scored higher than each other as well as where they scored equally. [6].  
The self-reported questionnaire detected 97% of patients with scores >2 at consultation 
and 86% with scores >3. The sensitivity is 95% (95% CI: 87 - 98) for detection of scores 
> 2 on the self-reported questionnaire compared to scores at consultation while specificity 
was only 35% (95% CI: 23-48). 
 
Discussion 
The SOMA-score was developed to perform intra- and inter trials comparisons of normal 
tissue toxicity after radiation therapy. The SOMA score involves both a subjective, 
objective, medical management and analytic part [7]. We have only used the subjective 
part in our study, as this is the only part that can be used in a self-reported questionnaire. 
However, caution must be advised as the Soma scores were developed for use in an 
interview setting and not as a patient self-reported questionnaire. There was, on the other 
hand, a relatively good concordance between what the patients reported on the 
questionnaire and in the interview setting. 
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In this study composite LENT (Late effects normal tissue) scores are not used in 
agreement with Juliana Denekamp that promoted that individual scores must be 
compared and sums and divisions of scores may be misleading [8]. Similarly, it is hard to 
compare scores of different normal tissue effects graded equally. For example, it is not 
given that hourly urinary frequency that is graded as 4 equals refractory incontinence that 
has the same grade. It will be easier for the patient and doctor to decide on a treatment 
modality if it is possible to assess the risk of normal tissue toxicity when each symptom 
can be evaluated separately rather than in groups of severity. Another problem with the 
subjective SOMA score is that it does not separate mucus from bleeding from the rectum 
as bleeding is part of the objective parameters. For this reason, many still use the 
RTOG/EORTC toxicity scores [9].  
 
The response rate to the mailed questionnaire was satisfactory as 65% replied and the 
surviving patient population was quite old at that time. (Those who did not reply had a 
median age of 75 years and we did not have information whether a large proportion of 
these patients may be disabled from other causes or institutionalized etc.). Of those who 
replied, 79% showed up for consultation and many expressed gratitude for being 
followed up. 
 
With a median follow-up time of 6,9 years in this study most late radiation effects should 
have been manifested. And even though there are reports that late radiation sequelae may 
fade with time, [10,11] the 4 months interval between the filling of the self reported 
questionnaire and the interview should have little impact on the results.  
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The toxicity results scored by clinician in our series can be compared to that of other 
studies [11]. Grade 3 and 4 urinary toxicity were rare, both reported by patient and 
interviewer. The most frequent urinary grade 2 toxicity reported by the patients was 
25,9% for urinary frequency and during interview 19,5%. Decreased stream, which was 
self-reported in 20,6% of patients and by clinician 26,6% of patients. However, we had 
no registration of scores prior to treatment and corrections for the natural development in 
the normal population was not done. Our results can thus only tell something about the 
patients’ subjective complaints at the time of assessment and can not directly be related to 
the therapy. Grade 3 and 4 rectal toxicity was rare. The only grade 4 reported was for 
sphincter control. The most frequent grade 2 score were mucus discharge or bleeding, 
41,0% and 4,7%, reported by the patients and interviewer, respectively. This large 
discrepancy between the self-reported and interview reported scores may be due to 
interpretation error by the patient as mucosal loss probably needs a better description in a 
patient questionnaire than what we used. 
The agreement between the patients and interviewer was however generally good. For the 
different symptoms, the range for which the interviewer and patient scored the same 
grade was from 37,5% to 86,2%, the average being 56,5%. Where there was a 
disagreement in the grade, the patients generally scored higher than the interviewer for all 
symptoms. This phenomenon has also been reported by others and will be discussed 
below. The highest difference was for mucus and bleeding from rectum, where 36,5% of 
the patients evaluated the symptoms to be two grades or higher symptom score than the 
interviewer did. Overall 58% reported higher in the self-assessment than the interview 
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setting for this symptom score. While mucus may be a quite innocent symptom, bleeding 
from the rectum may have severe consequences. However, bleeding may be from 
haemorrhoids and may not be due to radiation proctitis. The symptom registration of 
bleeding as a screening procedure may be useful even though the sensitivity is high and 
specificity is low. Rectal bleeding has also been used as an endpoint in several other 
studies, especially in studies of dose-volume constraints [12]. 
 
The systematic approach with specific list of symptom questions may reveal a larger 
number of symptoms than the patients would report spontaneously [13]. The use of 
questionnaires mentioning multiple possible symptoms may record symptoms more 
effectively than interviewing the patients [7]. There may, however, be many pitfalls in 
interpreting patients versus clinician’s reports of symptoms. But, generally, patient 
symptom reporting may add to the symptom monitoring and may provide a low cost 
useful tool for screening for sequelae. In our series we found that patients assigned 
greater severity to symptoms than the clinician. This is also in accordance with other 
studies using other questionnaires. Most studies found that the patients reported more 
symptoms and greater severity of symptoms, or that the patients and interviewers 
reported symptoms had high agreement, and that when there was a difference the patient 
usually reported more symptoms. We failed to find any studies were the clinicians report 
more symptoms than the patients. 
In two different studies regarding symptoms in patients with gynaecological cancer, there 
was a high agreement between the symptoms the patients reported using a questionnaire 
and the observer reported symptoms [14,15].  
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Comparing doctors and patients reports of symptoms after prostate irradiation, Lilleby et 
al found that the patient usually reported more symptoms [16]. Watkins-Bruner et al 
found that medical professionals underreported symptoms compared to when self-
reported by the patient using quality of life instruments after radiation therapy for 
prostate cancer [17]. Litwin et al have compared urologists’ assessment of symptoms to 
patients’ in patients with prostate cancer, and found that the urologists underestimated the 
symptoms [18]. Similarly, after radiotherapy the clinicians underreported the severity of 
symptoms compared to patients answering a questionnaire, in patients with cancer in the 
oral cavity, larynx and pharynx. The conclusion was that patient’s selfreport of symptoms 
is a more sensitive method for evaluating side effects than clinicians evaluation [19]. 
Meirovitz et al compared the grading of xerostomia severity after radiotherapy by the 
patients themselves, clinicians and to measurement of a major salivary gland flow. They 
found a correlation between the symptoms patients reported themselves and the salivary 
gland flow, but no significant correlation between the observer grading and the salivary 
gland flow measurement or the patient self-report of symptoms. The clinicians 
underestimated the severity of xerostomia [20]. Bjordal et al also found that found that 
the patient reported more symptoms and a lower quality of life than the clinician did after 
cancer treatment [21]. A study comparing symptoms after chemotherapy reported by the 
patient using a questionnaire with physicians’ reported symptoms, found that the patients’ 
reports were more sensitive and thus better suited for the investigation of symptoms [22]. 
Vistad et al found that physicians underreport symptoms after radiotherapy for cervical 
cancer [23]. Other studies have found that patients and the interviewer report similar 
amount and degree of symptoms. Basch et al compared side effects reported by the 
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patient and clinician in lung and genitourinary cancer clinics. They found that the 
agreement between the groups was high. Were there was not agreement patients reported 
more severe symptoms. These results can be compared to what we found in our study. 
Basch et al also found that difference between the groups rarely was sufficient enough 
that it would have any effect on deciding whether to start treatment of the symptoms or 
not [6].  
Clinicians may have a tendency to underestimate symptom severity, and others have 
indicated that this may have important implications for interventions [24]. 
The above-mentioned studies are all in concordance with our findings. However these 
studies used different methods and questionnaires. In our study, the same questionnaire 
(only with slight modification) was used by both patients as well as the experienced 
research nurse. In many studies the patients and clinicians generally used different forms, 
which can be a source for misinterpretation, although the important factor here is how 
sensitive the different methods are for discovering the side effects. 
 
The underestimations of symptoms by the interviewer may be unintentionally due to the 
fact that patients may have a tendency to “please the doctor” and especially men 
confronted with female health care workers. [25]. This may be part of the explanation 
why clinicians usually scored lower symptoms than the patients themselves [25,26]. 
Other reasons might be that the clinicians have a busy schedule and the time spend on 
each patient is not enough to let the patient come forward with all their symptoms. This 
may be minimized if one uses self-report questionnaires. 
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A potential weakness in our study is the fact that the same research nurse did all the 
interviews. The interviewer may have effect on the results, especially if there are few 
interviewers, as in our, where there was only one [25]. On the other hand, this may 
contribute to consistent scoring. 
 
 
The use of self-reported questionnaire may benefit the patients as sequelae may be 
detected and possible dealt with, but in addition, important quality indicators of the 
service may be gathered. The use of self-reported outcomes saves resources compared to 
ordinary specialist consultations. However, many factors need to be considered in 
designing the questionnaires for detection of treatment-related sequelae and quality of 
life. Since the main goal of our study was to evaluate if a self-assessment questionnaire 
was an effective screening tool for late toxicity after radiotherapy, we did not assess pre-
treatment symptoms. Pre-treatment symptoms are an important predictor of post-
treatment symptoms, and should therefore be included in trials comparing different 
treatment modalities [27,11]. 
 
As in so many other parts of medicine, other factors that may influence the subjective 
experience of urinary and rectal morbidities after treatment. Comorbity and even 
socioeconomic status should also be taken into account when assessing the outcome of 
treatment [28,29]. The National Urological Cancer Group in Norway (NUCG) has now 
started a national survey where patient recorded symptoms are registered prospectively 
and factors as genefactors, age, level of education, personality traits, co-morbidity as well 
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as pre-treatment bowel and bladder function are considered from patients receiving 
radical therapy for prostate cancer, both surgical- and radiotherapy. 
Similarly, patient reported outcomes in cancer care and trials are now advocated [30,31].  
Our results indicate that the self-reported questionnaire used was a very sensitive method 
of detecting toxisity scores > 2 compared to scores at consultation. The specificity was 
however relatively low as the patients generally scored higher on the self-reported forms 
than clinician during consultation. . But as we have discussed above, it is hard to tell if 
the clinicians-reported symptom scores are more correct than what the patients scores. It 
may well be that the patients are more correct.  
Conclusion 
The use of a self-reported questionnaire with the subjective parameters of urinary and 
rectal normal tissue reactions in the SOMA scales seems to be sensitive method for low 
cost screening for late normal tissue sequelae after radiotherapy for prostate cancer as 
part of a long term follow up strategy. 
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Fig 1 
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Table 1 Toxicity scores 
 Grade 1 Grade 2 Grade 3 Grade 4 
Bladder/Urethra:     
Dysuria 22,4% (8,6%) 11,2% (0) 0,6% (0) 0,6 (0,8) 
Frequency 38,9%(30,5%) 25,9%(19,5%) 9,9%(9,4%) 3,7%(0,8%) 
Hematuria 9,8% (6,3%) 5,5%(0,8%) 0,6% (0%)  
Incontinence  22,4%(14,8%) 6,8%(1,6%) 1,9% (0) 5,6% (5,5%) 
Decreased stream 29,4%(9,4%) 20,6%(26,6%) 15,6%(1,6%) 0,6% (0,8%) 
     
Rectum:     
Tenesmus 6,3% (3,9%) 4,4% (1,6%) 0,6% (0%)  
Mocosal loss  16,8%(10,9%) 41,0%(4,7%) 3,7% (2,3%)  
Stool frequency 55,2%(64,1%) 2,5% (4,7%) 0,6% (0,8%) 4,3% (0%) 
Sphincter control 23,0%(17,2%) 39,8% (7,8%) 3,7% (10,9%)  
Pain  28,2% (7,0%) 11,0%(3,1%) 1,2% (0,8%)  
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Appendix1
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Appendix2
 17 
Appendix3
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Legends 
 
Figure 1: Agreement or disagreement between self-assessment and clinician in toxicity. 
Self-assessment scores higher and interview scores higher, left and right respectively. In 
the middle the scores are the same for both self-assessment and interview.. * denotes 
score less than 3,0%. 
Table 1: Self-reported subjective toxicity scores are shown in black and scores at 
interview are shown in red.  
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